Inhibrx Biosciences Inc.(INBX)

Biotechnology · La Jolla, CA

$94.43-0.13 (-0.14%)

Delayed quote: Oct 6, 2026, 2:25 PM EDT

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T18:27:03.916Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:27:03.916Z.

Quote observation: 2026-10-06T18:25:02.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,385,400,094
TTM free cash flow · period ending 2026-06-30: -131,926,000

FMP input reference: 771dc6670e9772695969b0bf6104b917a4d7f40f340cdb77ec2424dd20cacd43

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

INBX Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

INBX Competitors' Price/FCF Ratio

INBX

Inhibrx Biosciences Inc.

Current

Market Cap

$1.39B

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TSHA

Taysha Gene Therapies, Inc.

vs INBX

Market Cap

$1.40B

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PNTG

The Pennant Group, Inc.

vs INBX

Market Cap

$1.41B

Price/FCF Ratio

54.22

TTM Avg

40.41

3Y Avg

45.21

5Y Avg

44.82

KLRA

Kailera Therapeutics, Inc.

vs INBX

Market Cap

$1.41B

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ANAB

AnaptysBio, Inc.

vs INBX

Market Cap

$1.42B

Price/FCF Ratio

78.57

TTM Avg

258.29

3Y Avg

258.29

5Y Avg

172.61

OMER

Omeros Corporation

vs INBX

Market Cap

$1.34B

Price/FCF Ratio

N/A

TTM Avg

2.59

3Y Avg

2.60

5Y Avg

2.60

BRVE

Braveheart Bio, Inc.

vs INBX

Market Cap

$1.43B

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RARE

Ultragenyx Pharmaceutical Inc.

vs INBX

Market Cap

$1.43B

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COAG

Hemab Therapeutics Holdings, Inc. Common Stock

vs INBX

Market Cap

$1.33B

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HCSG

Healthcare Services Group, Inc.

vs INBX

Market Cap

$1.44B

Price/FCF Ratio

9.54

TTM Avg

9.98

3Y Avg

22.18

5Y Avg

99.17

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Inhibrx Biosciences Inc. (INBX)	$1.39B	N/A	N/A	N/A	N/A
Taysha Gene Therapies, Inc. (TSHA)vs ›	$1.40B	N/A	N/A	N/A	N/A
The Pennant Group, Inc. (PNTG)vs ›	$1.41B	54.22	40.41	45.21	44.82
Kailera Therapeutics, Inc. (KLRA)vs ›	$1.41B	N/A	N/A	N/A	N/A
AnaptysBio, Inc. (ANAB)vs ›	$1.42B	78.57	258.29	258.29	172.61
Omeros Corporation (OMER)vs ›	$1.34B	N/A	2.59	2.60	2.60
Braveheart Bio, Inc. (BRVE)vs ›	$1.43B	N/A	N/A	N/A	N/A
Ultragenyx Pharmaceutical Inc. (RARE)vs ›	$1.43B	N/A	N/A	N/A	N/A
Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›	$1.33B	N/A	N/A	N/A	N/A
Healthcare Services Group, Inc. (HCSG)vs ›	$1.44B	9.54	9.98	22.18	99.17

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Price/FCF Ratio: N/A

INBX Price/FCF Ratio Metrics

INBX Competitors' Price/FCF Ratio

Free Cash Flow Valuation

Price/FCF Ratio Formula & Definition

Related Metrics